Zobrazeno 21 - 30
of 327
pro vyhledávání: ''
Autor:
Xiaojuan Zhang, Xuanxuan Zheng, Jinpo Yang, Peng Li, M. Zhang, Xiangtao Yan, Zhiyong Ma, Huijuan Wang, Guowei Zhang
Publikováno v:
Lung Cancer. 128:6-12
Objective: The objective of this study was to investigate whether first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy improves the prognosis of patients with advanced non-sm
Autor:
Akihiko Ito, Kaoru Tanaka, Kazuhiko Nakagawa, Yasushi Nakamura, Masayuki Takeda, Hitomi Sakai, Kazuto Nishio, Hidetoshi Hayashi, Kazuko Sakai
Publikováno v:
Lung Cancer. 127:59-65
Objectives Immune-checkpoint inhibitors (ICIs) are now an established therapeutic option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however, whether cytotoxic chemotherapy affects the immune microenvironment in NSCLC
Publikováno v:
Lung Cancer. 127:53-58
Objectives To evaluate treatment patterns, physician-assessed overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) among third-line (3L)-plus small cell lung cancer (SCLC) patients. Materials and methods Retrospecti
Autor:
Min Huang, Laurie Lévy-Bachelot, Christos Chouaid, Pierre Levy, E. Clay, Lionel Bensimon, Aurélie Millier
Publikováno v:
Lung Cancer
Lung Cancer, Elsevier, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩
Lung Cancer, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩
Lung Cancer, Elsevier, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩
Lung Cancer, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩
Introduction In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive
Autor:
Alexis B. Cortot, David Planchard, Hélène Doubre, Bénédicte Mastroianni, Sylvestre Le Moulec, Florian Guisier, Lionel Falchero, Jennifer Arrondeau, Aldo Renault, Isabelle Monnet, Laurent Greillier, Marie Wislez, L. Gérinière, Jean Bernard Auliac, Chantal Decroisette, Maurice Pérol, Eric Pichon, Catherine Daniel, Christos Chouaid, Roland Schott
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
International audience; Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimert
Autor:
Kohei Otsubo, Satoshi Anai, Yasuto Yoneshima, Yoichi Nakanishi, Eiji Iwama, Isamu Okamoto, Kentaro Tanaka
Publikováno v:
Lung Cancer. 126:156-161
Etoposide is a key agent in the treatment of small cell lung cancer (SCLC). Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, sugges
Autor:
Nooshin Hashemi Sadraei, Lingling Du, Pingfu Fu, Tarek Mekhail, Sulsal Haque, Carol Farver, Jahnavi Gollamudi, Neelesh Sharma, Stanton L. Gerson, Stefanie Avril, Afshin Dowlati, Yan Feng, Nathan A. Pennell
Publikováno v:
Lung Cancer. 126:48-54
Objective The antifolate chemotherapy agent pemetrexed has been widely used to treat non-small-cell-lung-cancer (NSCLC), but there is no clinically validated biomarker to select patients likely to respond. The aim of this study was to assess two prot
Autor:
Hisatsugu Goto, Hiroshi Kawano, Soji Kakiuchi, Satoshi Sakaguchi, Masaki Hanibuchi, Yuko Toyoda, Fumitaka Ogushi, Kenji Otsuka, Yasuhiko Nishioka, Eiji Shimizu, Hiroshi Nokihara, Masahiko Azuma, Takashi Haku, Shinji Atagi, Mayo Kondo
Publikováno v:
Lung Cancer. 125:93-99
Objectives The clinical benefit of chemotherapy and the appropriate regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remain unclear. To fulfill this unmet medical need, we conducted a phase II study to eluc
Autor:
Amita Patnaik, Harry Raftopoulos, James Chih-Hsin Yang, Shirish M. Gadgeel, Leena Gandhi, Matthew A. Gubens, Vassiliki A. Papadimitrakopoulou, Lecia V. Sequist, Ralph Hauke, Robert Bachman, Hossein Borghaei, James P. Stevenson, Liza C. Villaruz, Sanatan Saraf, Corey J. Langer
Publikováno v:
Lung Cancer. 125:273-281
Objectives Platinum-based chemotherapy for advanced non–small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021 (Clinicaltrials.gov,
Autor:
Miyako Satouchi, Ken Uchibori, Motoko Tachihara, Chiyuki Kokan, Yoshiko Urata, Keisuke Aoe, Kazuyuki Kobayashi, Kentaro Iwanaga, Akemi Sato, Naoko Sueoka-Aragane, Satoshi Morita, Tomonori Hirashima, Nobuyuki Katakami, Shunichi Negoro, Takako Inoue, Fumio Imamura, Masahide Mori
Publikováno v:
Lung Cancer. 124:65-70
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression caused by acquir